FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in ...

During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ...

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover ...

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of ...

A novel trispecific antibody, JNJ-5322, shows remarkable efficacy in treating multiple myeloma, achieving a 100% response ...

Recent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially ...

Nemvaleukin alfa shows promising antitumor activity in advanced melanoma and renal cell carcinoma, with manageable safety in ...

FDA designates olomorasib and pembrolizumab as breakthrough therapy for advanced KRAS G12C-mutant lung cancer, showing ...

The FDA approves INLEXZO, a groundbreaking treatment for bladder cancer, offering hope for patients unresponsive to traditional therapies.

During a live event, Christopher J. Ferreri, MD, discussed findings on dose and schedule modifications of talquetamab in ...

FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this ...

Myeloma research faces funding uncertainties, yet collaboration and innovation drive optimism for breakthroughs in treatment ...